Nebula Research & Development LLC Takes Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Nebula Research & Development LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 31,645 shares of the company’s stock, valued at approximately $697,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. True Wind Capital Management L.P. lifted its stake in shares of Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after acquiring an additional 2,130,386 shares during the last quarter. FMR LLC grew its holdings in Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company’s stock worth $233,988,000 after acquiring an additional 5,004,587 shares during the period. Axon Enterprise Inc. bought a new position in shares of Cellebrite DI during the 4th quarter worth about $198,270,000. Voss Capital LP boosted its position in shares of Cellebrite DI by 1.2% during the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company’s stock worth $71,377,000 after purchasing an additional 39,700 shares in the last quarter. Finally, Pertento Partners LLP boosted its position in shares of Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after purchasing an additional 626,373 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Up 0.7 %

NASDAQ:CLBT opened at $19.78 on Tuesday. The business’s 50-day moving average price is $18.73 and its two-hundred day moving average price is $20.15. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The stock has a market cap of $4.74 billion, a P/E ratio of -14.23, a PEG ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CLBT. Lake Street Capital raised their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.